Literature DB >> 22743851

The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese.

Ya-Feng Zhang1, Ling Qin, Ping-Chung Leung, Timothy C Y Kwok.   

Abstract

In this study we analyzed the independent effect of angiotensin-converting enzyme (ACE) inhibitor use on bone loss in elderly Chinese. The subjects were from two cohort studies which investigated the risk factors of osteoporotic fractures in Hong Kong-dwelling elderly Chinese. A total of 2161 subjects (1280 male, 881 female) were selected for this analysis. The results showed that unadjusted annualized percentage bone loss of male ACE inhibitor users was not different from non-users; however, female ACE inhibitor users had significantly greater bone loss both in total hip and femoral neck than non-users. After adjusting for significant confounders, female continuous ACE inhibitor users had significantly greater bone loss at total hip and femoral neck. In conclusion, continuous use of ACE inhibitors over 4 years was associated with increased bone loss in total hip and femoral neck in older Chinese women.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743851     DOI: 10.1007/s00774-012-0363-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  28 in total

Review 1.  Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.

Authors:  José López-Sendón; Karl Swedberg; John McMurray; Juan Tamargo; Aldo P Maggioni; Henry Dargie; Michal Tendera; Finn Waagstein; Jan Kjekshus; Philippe Lechat; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

Review 2.  Renin-angiotensin system: biochemistry and mechanisms of action.

Authors:  M J Peach
Journal:  Physiol Rev       Date:  1977-04       Impact factor: 37.312

3.  Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.

Authors:  R Hatton; M Stimpel; T J Chambers
Journal:  J Endocrinol       Date:  1997-01       Impact factor: 4.286

4.  The determinants of bone mineral density in Chinese men--results from Mr. Os (Hong Kong), the first cohort study on osteoporosis in Asian men.

Authors:  E M C Lau; P C Leung; T Kwok; J Woo; H Lynn; E Orwoll; S Cummings; J Cauley
Journal:  Osteoporos Int       Date:  2005-09-21       Impact factor: 4.507

5.  beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures.

Authors:  Ian R Reid; Gregory D Gamble; Andrew B Grey; Dennis M Black; Kristine E Ensrud; Warren S Browner; Douglas C Bauer
Journal:  J Bone Miner Res       Date:  2004-12-06       Impact factor: 6.741

6.  Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus.

Authors:  P Gerdhem; A Isaksson; K Akesson; Karl J Obrant
Journal:  Osteoporos Int       Date:  2005-04-12       Impact factor: 4.507

7.  Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients.

Authors:  H Koshida; R Takeda; I Miyamori
Journal:  Hypertens Res       Date:  1998-12       Impact factor: 3.872

Review 8.  Osteoporosis epidemiology update.

Authors:  Zoe A Cole; Elaine M Dennison; Cyrus Cooper
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

9.  Use of beta-blockers and risk of fractures.

Authors:  Raymond G Schlienger; Marius E Kraenzlin; Susan S Jick; Christoph R Meier
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

10.  Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone.

Authors:  Melita M Dvorak; Cyrille De Joussineau; D Howard Carter; Trairak Pisitkun; Mark A Knepper; Gerardo Gamba; Paul J Kemp; Daniela Riccardi
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

View more
  13 in total

1.  Association between the ACE gene I/D polymorphism and osteoporosis in a Turkish population.

Authors:  B Cakmak; A Inanir; N Karakus; O Ates; S Yigit
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

2.  Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men.

Authors:  Nahid Rianon; Catherine G Ambrose; Hannah Pervin; Melissa Garcia; Scherezade K Mama; Ann V Schwartz; Brendan Lee; Tamara Harris
Journal:  Arch Osteoporos       Date:  2017-10-28       Impact factor: 2.617

3.  The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative.

Authors:  L D Carbone; S Vasan; R L Prentice; G Harshfield; B Haring; J A Cauley; K C Johnson
Journal:  Osteoporos Int       Date:  2019-06-17       Impact factor: 4.507

4.  Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.

Authors:  Y Zhang; L Wang; Y Song; X Zhao; M S Wong; W Zhang
Journal:  Osteoporos Int       Date:  2015-10-06       Impact factor: 4.507

5.  ACE inhibitors and the risk of fractures: a meta-analysis of observational studies.

Authors:  Yan-Zhen Cheng; Zhen-Zi Huang; Ze-Feng Shen; Hai-Yang Wu; Jia-Xin Peng; Mary Miu Yee Waye; Shi-Tao Rao; Li Yang
Journal:  Endocrine       Date:  2016-12-19       Impact factor: 3.633

6.  Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

Authors:  Kara L Holloway-Kew; Amelia G Betson; Kara B Anderson; James Gaston; Mark A Kotowicz; Wan-Hui Liao; Maciej Henneberg; Julie A Pasco
Journal:  Arch Osteoporos       Date:  2021-09-18       Impact factor: 2.617

7.  Association of Circulating Renin and Aldosterone With Osteocalcin and Bone Mineral Density in African Ancestry Families.

Authors:  Allison L Kuipers; Candace M Kammerer; J Howard Pratt; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Joseph M Zmuda
Journal:  Hypertension       Date:  2016-03-14       Impact factor: 10.190

8.  Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes.

Authors:  Teng-Yue Diao; Hai Pan; Sa-Sa Gu; Xi Chen; Fang-Yi Zhang; Man-Sau Wong; Yan Zhang
Journal:  J Bone Miner Metab       Date:  2013-08-10       Impact factor: 2.626

9.  Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.

Authors:  Suguru Yamamoto; Ryo Kido; Yoshihiro Onishi; Shingo Fukuma; Tadao Akizawa; Masafumi Fukagawa; Junichiro J Kazama; Ichiei Narita; Shunichi Fukuhara
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

10.  The relationship between angiotensin-converting enzyme (ACE) insertion (I) / deletion (D) polymorphism, serum ACE activity and bone mineral density (BMD) in older Chinese.

Authors:  Ya-Feng Zhang; Hong Wang; Qiong Cheng; Ling Qin; Nelson Ls Tang; Ping-Chong Leung; Timothy Cy Kwok
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017-01       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.